A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP
研究成果 › 査読
37
被引用数
(Scopus)